Market Sector Leaders
Samuel Broder, M.D. - Senior Vice President, Health Sector
Dr. Broder brings more than 30 years of internal medicine and oncology experience to Intrexon. Most notably, Dr. Broder was Director of the National Cancer Institute (NCI) during the Reagan administration, a position he held for six years.
Before joining Intrexon in 2012, Dr. Broder was the Executive Vice President for Medical Affairs and Chief Medical Officer at Celera Corporation, now a division of Quest Diagnostics, where he helped advance the human genome project. While directing NCI, he oversaw the development of many anti-cancer therapeutic agents, helped launch a number of large-scale clinical trials related to the prevention, diagnosis and treatment of cancer, and launched the highly successful SPORE Program.
Dr. Broder also played a major role in developing the first three FDA-approved AIDS treatments. He has served as a board member and as a consultant for numerous pharmaceutical and biotech companies in the U.S. and abroad. Dr. Broder has authored or co-authored more than 340 scientific publications, holds multiple patents, and was elected to the Institute of Medicine of the National Academy of Sciences in 1993. Dr. Broder earned his M.D. from the University of Michigan Medical School in Ann Arbor in 1970.
Thomas R. Kasser, Ph.D. - Senior Vice President, Food Sector
Dr. Kasser brings over 25 years of business management experience in the biotechnology and life sciences industries. He was most recently President and Chief Executive Officer of Angionics, Inc., an early-stage biotech company focused on novel anti-angiogenic technology directed at therapies for cancer and ocular diseases.
Prior to Angionics, he was a Covance Corporate Vice President and General Manager of Covance Research Products. Dr. Kasser had over 20 years of experience at Monsanto Company both in commercial as well as scientific leadership roles, including tenures as General Manager of Monsanto Choice Genetics, directing new product development for the Nutrition and Consumer products business, and managing clinical safety and efficacy trials under the jurisdiction of the FDA Center for Veterinary Medicine.
Dr. Kasser was designated a Monsanto Fellow in recognition of his scientific and technical excellence. He currently serves on the Board of Directors for AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in aquaculture. Dr. Kasser received his Ph.D. in Nutrition from the University of Georgia and an M.S. in Animal Nutrition from the Pennsylvania State University. He also received an M.B.A. from Washington University - St. Louis.
Robert F. Walsh, III – Senior Vice President, Energy Sector
Mr. Walsh joins Intrexon with more than 30 years of global petroleum and chemical industry experience, including 26 years at Royal Dutch Shell. Most recently, Mr. Walsh was Chief Commercial Officer of ZeaChem, Inc., a private industrial biotechnology company developing a cellulose-based bio-refinery platform capable of producing advanced fuels and chemicals.
Previously, Mr. Walsh was CEO and Executive Board member of Aurora Biofuels, Inc., a private industrial biotechnology company developing algae based alternative fuels and animal protein. He was also President and Executive Board Member of LS9, Inc., a private industrial biotechnology company developing biofuels using synthetic biology. Under his leadership, the World Economic Forum honored LS9 as a 2007 Technology Pioneer.
At Shell, Mr. Walsh held senior manufacturing, supply, distribution, and strategic planning positions in North America and Europe, including General Manager Supply-Europe for Shell Europe Oil Products.
He earned his B.S. in Chemical Engineering from Purdue University.
Nick Macris – Vice President, Environment Sector
Mr. Macris brings 15 years of business and technical experience in the natural product, industrial and specialty technical industries to Intrexon. Mr. Macris joins the company from Marrone Bio Innovations, an early-stage biopesticide company focused on natural product solutions for disease and pest management in plants and aquatic systems where he was Vice President of Business Development.
Mr. Macris has worked in various roles at several other agricultural and environmental biotech companies, including business development at Purifics ES Inc., corporate development and mergers and acquisitions at FMC Corporation, and corporate level platform development as well as business development activities to establish a biopesticide portfolio at Rohm & Haas.
Prior to pursuing his M.B.A., Mr. Macris worked in the specialty chemical division and the tape product engineering group at 3M Canada. Mr. Macris earned an M.E.Sc. in Chemical and Biochemical Engineering from the University of Western Ontario and an M.B.A. from the Richard Ivey Business School in London, Canada.
Peter Seufer-Wasserthal, Ph.D., Vice President, Business Development, Europe and Asia
Dr. Seufer-Wasserthal brings more than 20 years of experience in business development and licensing, as well as enzyme technology and chemistry, to Intrexon.
Prior to joining Intrexon, Dr. Seufer-Wasserthal was Senior Vice President of Pharmaceuticals at Codexis, Inc., where he was responsible for closing numerous licensing, research and supply agreements, and adapting IP strategy to increase account penetration. Before Codexis, Inc., Dr. Seufer-Wasserthal managed drug discovery collaborations, licensed pre-clinical candidates and purchased services for drug development projects as Senior Vice President of Clinical Development at Morphochem AG.
He holds a Ph.D. in organic chemistry from the Technical University of Graz.